LNTH Q1 2025 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$373M+0.8% YoY

Gross Profit

$238M63.8% margin

Operating Income

$102M27.4% margin

Net Income

$73M19.6% margin

EPS (Diluted)

$1.02

QoQ Revenue Growth

-4.7%

Cash Flow

Operating Cash Flow

$108M

Free Cash Flow

$99M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$891M

Stockholders' Equity

$1.2B

Cash & Equivalents

$939M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$373M	$370M	+0.8%
Gross Profit	$238M	$252M	-5.6%
Operating Income	$102M	$100M	+1.7%
Net Income	$73M	$131M	-44.3%

Revenue Segments

Product

$367M33%

PYLARIFY

$258M23%

Radiopharmaceutical Oncology

$258M23%

Total Precision Diagnostics

$104M9%

DEFINITY

$79M7%

Techne Lite

$20M2%

Strategic Partnerships And Other

$11M1%

License and Royalty Revenues

$6M1%

Other Precision Diagnostics

$5M0%